<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038268</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0361</org_study_id>
    <nct_id>NCT04038268</nct_id>
  </id_info>
  <brief_title>Criteria Used by Health Professionals on the Selection of Allergen Immunotherapy in Real Clinical Practice</brief_title>
  <acronym>CHOICE</acronym>
  <official_title>Criteria Used by Health Professionals on the Selection of Allergen Immunotherapy in Real Clinical Practice: an International E-survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background : Allergen Immunotherapy (AIT) is the only etiological treatment for allergic
      respiratory diseases. In order to improve the competence on the use of AIT, it is important
      to extend the investigator's knowledge on its use in routine clinical practice, outside the
      experimental setting of clinical trials, in real life population of patients receiving AIT.

      Objective: To evaluate the clinical criteria used by treating clinicians and by the patients
      themselves, when establishing AIT as treatment in a patient with respiratory disease caused
      by an IgE-dependent-hypersensitivity to aeroallergens Methods: In 6 country (Denmark, France,
      Germany, Norway, Spain &amp; Sweden), the national coordinator will be directly responsible for
      selection of Survey Doctor's participants (Investigators).

      During 12 months:

        -  Firstly, each investigator will complete the Survey Doctor, online, on SurveyMonkey
           platform to explain what are the key drivers in Allergen Immunotherapy (AIT) selection
           (Doctors' Questionnaire, DQ).

        -  On the other hand, at each AIT prescription to a patient, doctors will complete the
           Survey Patient, on the same platform, to explain how and why they have chosen this type
           of AIT (Patients' Questionnaire, PQ).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical criteria in AIT</measure>
    <time_frame>1 day</time_frame>
    <description>Clinical criteria used by treating clinicians and by the patients themselves, when establishing AIT as treatment in a patient with respiratory disease. These are called &quot;drivers of prescription&quot;.
caused by an IgE-dependent-hypersensitivity to aeroallergens Among the different criteria selected by participants, order of priority of AIT drivers will be established</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Allergen Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Adults and children, males and females, with IgE mediated pollen, house dust mites, animal dander and moulds respiratory allergy who will initiate aeroallergen AIT, either SCIT, SLIT-drops or SLIT-tablets according to real life clinical standards of practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prescribers</arm_group_label>
    <description>Doctors who are currently prescribing AIT as part of their regular clinical practice</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with IgE mediated hypersensitivity to aeroallergens who will initiate AIT, either
        SCIT, SLIT-drops or SLIT-tablets according to real life clinical standards of practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with IgE mediated respiratory allergy

          -  Patients who will initiate any type of aeroallergen AIT according to real life
             clinical standards of practice

          -  Any type of aeroallergen for AIT will be included : pollen, house dust mite, animal,
             dander, moulds

          -  Patient who is under the care of the Doctor participating in the survey

        Exclusion criteria:

          -  Patients who refuse to give their informed consent

          -  Food immunotherapy

          -  Venom Immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Demoly</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davide CAIMMI, MD</last_name>
    <phone>467336112</phone>
    <phone_ext>33</phone_ext>
    <email>davide.caimmi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascal Demoly, PhD</last_name>
    <phone>467336112</phone>
    <phone_ext>33</phone_ext>
    <email>pascal.demoly@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide CAIMMI, MD</last_name>
      <phone>467336112</phone>
      <phone_ext>33</phone_ext>
      <email>davide.caimmi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Real Clinical Practice</keyword>
  <keyword>Respiratory disease</keyword>
  <keyword>Aeroallergens</keyword>
  <keyword>IgE-dependent hypersensitivity</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

